Next 10 |
home / stock / oxbdf / oxbdf news
2024-04-30 15:22:58 ET More on Oxford Biomedica plc Oxford Biomedica plc (OXBDF) Q4 2023 Earnings Call Transcript Historical earnings data for Oxford Biomedica plc Financial information for Oxford Biomedica plc Read the full article on Seeking Alpha F...
2024-04-29 13:05:24 ET Oxford Biomedica plc (OXBDF) Q4 2023 Earnings Conference Call April 29, 2024 08:00 ET Company Participants Frank Mathias - Chief Executive Officer Sébastien Ribault - Chief Commercial Officer Stuart Paynter - Chief Financial Officer ...
EXPRESS INC. DL-01 (02Z0:DU) is expected to report $-8.99 for Q4 2024 Oxford Biomedica (OXBDF) is expected to report for Q4 2023 Yaskawa Electric Corporation ADR (YASKY) is expected to report for Q4 2024 Express (02Z0:MU) is expected to report $-8.99 for Q4 2024 Express Inc. - Ord...
Oxford Biomedica (OXBDF) is expected to report for Q4 2023
2023-09-20 16:11:05 ET Oxford Biomedica plc (OXBDF) Q2 2023 Earnings Conference Call September 20, 2023 08:00 ET Company Participants Frank Mathias - CEO Sebastien Ribault - Chief Commercial Officer Stuart Paynter - CFO Conference Call Participants My...
Oxford Biomedica plc (OXBDF) Q2 2022 Results Conference Call September 15, 2022 08:00 AM ET Company Participants Rob Ghenchev - Chairman of the Board and Intern CEO Stuart Paynter - Chief Financial Officer Kyri Mitrophanous - Chief Scientific Officer Sophia B...
Oxford Biomedica press release ( OTCPK:OXBDF ): 1H GAAP EPS of 0.00p. Revenue of £64.03M (-21.2% Y/Y). Operating EBITDA loss and operating loss of £5.8M and £19.2M respectively. Cash at 30 June 2022 was £118.5M and £115.8M at 31 Augus...
U.K.-based biotech Oxford Biomedica ( OTCPK:OXBDF ) announced on Friday that the company entered into a new three-year partnership with AstraZeneca ( AZN ) to manufacture the Anglo Dutch pharma giant’s COVID-19 vaccine. The deal marks an expansion of the original ag...
Oxford Biomedica Plc (OXBDF) Q4 2021 Earnings Conference Call April 20, 2022, 8:00 AM ET Company Participants Dr. Roch Doliveux – Chairman, Interim Chief Executive Officer Sophia Bolhassan – Director of Investor Relations Kyri Mitrophanous – Chief Scientific Officer Stuar...
Oxford Biomedica (OTCPK:OXBDF) released Wednesday its FY21 preliminary results with revenue of £142.8M (+63% Y/Y). Revenues from bioprocessing and commercial development rose 87% linked to the commercial manufacturing of the adenovirus-based Oxford AstraZeneca CO...
News, Short Squeeze, Breakout and More Instantly...
EXPRESS INC. DL-01 (02Z0:DU) is expected to report $-8.99 for Q4 2024 Oxford Biomedica (OXBDF) is expected to report for Q4 2023 Yaskawa Electric Corporation ADR (YASKY) is expected to report for Q4 2024 Express (02Z0:MU) is expected to report $-8.99 for Q4 2024 Express Inc. - Ord...
Oxford Biomedica (OXBDF) is expected to report for Q4 2023
LONDON, UK / ACCESSWIRE / October 5, 2020 / Oxford Biomedica (OXB) is a pioneer and global leader in the development and manufacture of commercial-scale lentiviral vectors (LVVs), a critical component of cell and gene therapies (CGTs). An investment in OXB gives a broad exposure to this emer...